Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00774202 · ClinicalTrials.gov registry record · Phase 2
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00774202 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 17 participants.
The verdict
NCT00774202, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study is designed to compare the efficacy and safety of higher doses of Rituxan with a regimen combining standard doses of Rituxan + CVP in patients with chronic ITP who did not respond to or relapsed after standard doses of Rituxan. Patients eligible for this protocol will be stratified into two subgroups according to their initial response to Rituxan.
Interventions
- DRUG Rituxan, Cyclophosphamide, Vincristine, Prednisone
- DRUG Higher Dose of Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2003-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00774202
The ClinicalTrials.gov registry entry for NCT00774202 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituxan, Cyclophosphamide, Vincristine, Prednisone is the first listed.
NCT00774202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00774202 about?
NCT00774202 is a clinical study titled "Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP". This study is designed to compare the efficacy and safety of higher doses of Rituxan with a regimen combining standard doses of Rituxan + CVP in patients with chronic ITP who did not respond to or relapsed after standard doses of Rituxan. Patients eligible for this protocol will be stratified into t...
What is the current status of trial NCT00774202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2003-11. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00774202?
The interventions under investigation include: Rituxan, Cyclophosphamide, Vincristine, Prednisone (DRUG), Higher Dose of Rituximab (DRUG).
Who is sponsoring clinical trial NCT00774202?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.